Form 4: MapLight Therapeutics GC Executes Planned Stock Sale

General Counsel Kristopher Hanson sold 13,917 shares of MapLight Therapeutics common stock via a Rule 10b5-1 trading plan.

Summary

• Kristopher Hanson, General Counsel of MapLight Therapeutics, Inc., sold a total of 13,917 shares of voting common stock on May 4, 2026.
• The sales were executed in four tranches at weighted average prices ranging from $27.50 to $30.08 per share.
• Following these transactions, the reporting person retains beneficial ownership of 176,248 shares.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-established, automated trading plan.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, indicating the transaction was not based on non-public information.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on current valuation.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard corporate governance practice and typically does not reflect a change in company fundamentals or strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to liquidate equity positions while avoiding potential insider trading liability.

Stakeholder Impact

• Shareholders should note the reduction in insider holdings, though the pre-planned nature mitigates concerns regarding management sentiment.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Insider Trading, Form 4, Rule 10b5-1, General Counsel